AbbVie Inc (ABBV)vsViemed Healthcare Inc (VMD)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
VMD
Viemed Healthcare Inc
$9.96
+0.71%
HEALTHCARE · Cap: $380.22M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 22528% more annual revenue ($61.16B vs $270.28M). ABBV leads profitability with a 6.9% profit margin vs 5.5%. VMD trades at a lower P/E of 26.7x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
VMD
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+57.1%
Fair Value
$19.68
Current Price
$9.96
$9.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Revenue surging 25.5% year-over-year
Earnings expanding 29.8% YoY
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Moderate valuation
Smaller company, higher risk/reward
5.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : VMD
The strongest argument for VMD centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 25.5% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : VMD
The primary concerns for VMD are P/E Ratio, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while VMD is a growth play — different risk/reward profiles.
VMD carries more volatility with a beta of 1.16 — expect wider price swings.
VMD is growing revenue faster at 25.5% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 56/100). VMD offers better value entry with a 57.1% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Viemed Healthcare Inc
HEALTHCARE · MEDICAL DEVICES · USA
Viemed Healthcare, Inc. provides durable home medical equipment and post-acute respiratory health care services to patients in the United States. The company is headquartered in Lafayette, Louisiana.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?